重组人血管内皮抑制素联合TP方案治疗晚期非小细胞肺癌的临床观察(3)
 |
| 第1页 |
参见附件(2024KB，3页)。
[参考文献]
[1] Laskin JJ,Sandler AB. First-line treatment for advanced non small cell lung cancer[J]. Oncology(Williston Park),2005,19(13):1671-1680.
[2] Le_Chevalier T,Scagliotti G,Ntale R,et al. Gemcitabine in the treatment of NSCLC:meta analysis of survival and progression free survival data[J].Lung Cancer,2005,47(1):69-80.
[3] Folkman J. Tumor angiogenesis:therapeutic implications[J]. N Eng1 J Med,1971,285:1182-1186.
[4] Folkman J. Anti-angiogenesis in cancer therapy endostatin and its mechanisms of action[J]. Expt Cell Res,2006,312(5):594-607.
[5] 高斌斌,徐忠法. 抗肿瘤血管生成及其联合放化疗的研究进展[J]. 中华肿瘤防治杂志,2006,13(3):235-238.
[6] 隋刚 徐志飞,孙耀昌,等. 内皮抑素基因治疗对小鼠肿瘤组织内新生血管形成抑制作用的试验研究[J]. 中华肿瘤防治杂志,2006,13(12):904-907.
[7] 黄纯,李凯,魏熙胤,等. 晚期非小细胞肺癌循环血管内皮细胞水平研究[J]. 中华肿瘤杂志,2006,10(28):780-783.
[8] 蔡莉 隋广杰. 肺癌分子靶向性治疗研究的主要成就[J]. 中华肿瘤杂志,2004,26(3):129-134.
[9] Brandwijk RJ,Dings RP,Vander Linden E,et al. Anti-angiogenic and anti-tumor activity of recombinant anginex[J]. Biochem Biophys Res Com- mun,2006,349(3):1073-1078.
[10] Dudek AZ,Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer:correlation with treatment response and survival[J]. Cancer Invest,2005,23(3):193-200.
[11] Goon PK,Boos CJ,Stonelake PS,et al. Circulating endothelial cells in m alignant disease[J]. Future Oncol,2005,1(6):813-820.
[12] 李丽萍,曹骥,杨春. CD146与肿瘤的关系[J]. 中华肿瘤防治杂志,2007,14(8):635-637.
(收稿日期:2010-01-12)
您现在查看是摘要介绍页，详见PDF附件(2024KB，3页)。